PLK4,

Cunzheng Fan1, Nian Liu1, Ningyuan Hu1

  • 1Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District Shenyang 110016 PR China medchemzhao@163.com.

RSC medicinal chemistry
|October 8, 2025
PubMed
概括

开发了基于因达的新型化合物,以抑制Polo样酶4 (PLK4),这是细胞分裂的关键调节器和潜在的癌症标. 化合物C05表现出强大的抗癌活性和选择性,尽管代谢稳定性差,表明进一步药物开发的希望.